A PHASE 2, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, 4-ARM STUDY TO INVESTIGATE SYMPTOMS, FUNCTION, HEALTH-RELATED QUALITY OF LIFE AND SAFETY WITH REPEATED SUBCUTANEOUS ADMINISTRATION OF PONSEGROMAB VERSUS PLACEBO IN ADULT PARTICIPANTS WITH HEART FAILURE
Latest Information Update: 20 Jun 2025
At a glance
- Drugs Ponsegromab (Primary)
- Indications Heart failure
- Focus Therapeutic Use
- Acronyms GARDEN TIMI 74
- Sponsors Pfizer
Most Recent Events
- 18 Apr 2025 Status changed from active, no longer recruiting to discontinued.
- 07 Feb 2025 Status changed from recruiting to active, no longer recruiting.
- 27 Nov 2024 Planned End Date changed from 2 Mar 2026 to 27 May 2026.